History
Innovative Medicines based on
ImmunoModulatory Biologics
-
About us
-
History
Global biotechnology company
that benefits the world
2021
- 08
- Completion of 13 Bil. KRW Series A Funding by KB, Atinum, Partners, IMM and Timewise investment firms
- 04
- Completion of the trademark application
- 03
- Approval of the LMO facility
- 03
- The 1st annual shareholder meeting
- 02
- Certification of the venture company
- 01
- Completion of 4 Bil. KRW Seed Funding led by KB investment and Atinum investment
2020
- 12
- Certification of the company-affiliated research institute
- 11
- Relocation of the HQ and the research institute to Gwanggyo Central Biz Tower
- 11
- Worldwide exclusive in-licensing agreement for OXTIMA(IMB-101) with HK inno.N
- 10
- Patent application for the IMB platform technology
- 09
- Temporary research institute established at Gyeonggi Bio Center
- 08
- Establishment of IMBiologics Inc.
- President(CEO) : Gyongsik Ha
- 260, Changnyong-daero, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea